10-Q: Pacira BioSciences Reports Q3 2024 Results, Faces Patent Setback and Records Goodwill Impairment

Pacira BioSciences reported its Q3 2024 results, which included a goodwill impairment charge and a patent invalidation, alongside a modest revenue increase.

Summary

• Pacira BioSciences reported a net loss of $143.5 million for the third quarter of 2024, compared to a net income of $10.9 million in the same period last year.
• The company's total revenue increased by 3% to $168.6 million in Q3 2024, driven by a 3% increase in EXPAREL sales and a 91% increase in bupivacaine liposome injectable suspension sales.
• A significant goodwill impairment charge of $163.2 million was recorded due to a generic competitor approval and a patent invalidation.
• Operating expenses increased significantly to $308.1 million, primarily due to the goodwill impairment.
• The company's cash and cash equivalents stood at $246 million as of September 30, 2024.
• The company repurchased 837,240 shares of its common stock for a total cost of $25.1 million.
• The company's total liabilities were $772.1 million, while total stockholders' equity was $749.6 million.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive revenue growth but is heavily weighed down by a significant net loss, a large goodwill impairment, and a patent invalidation. The overall sentiment is negative due to these substantial financial and legal setbacks.

Positives

• Net product sales saw a modest increase of 3% in Q3 2024.
• iovera sales increased by 8% in Q3 2024 and 20% for the nine months ended September 30, 2024.
• Bupivacaine liposome injectable suspension sales increased significantly by 91% in Q3 2024 and more than 100% for the nine months ended September 30, 2024.
• The company has a new J-code for EXPAREL effective January 1, 2025, which will provide reimbursement when EXPAREL is used in the office setting and for office-based surgeries.
• Both EXPAREL and iovera qualify as eligible non-opioid pain management products under the NOPAIN Act, which will provide additional Medicare reimbursement beginning January 1, 2025.

Negatives

• The company reported a net loss of $143.5 million for Q3 2024.
• A significant goodwill impairment charge of $163.2 million was recorded.
• A U.S. District Court ruled that one of the company's patents was not valid.
• ZILRETTA revenue decreased by 1% in Q3 2024 due to a 6% decrease in kit volume.
• The company faces ongoing litigation related to its patents and intellectual property.

Risks

• The company faces competition from generic entrants for EXPAREL.
• The company is reliant on revenue from three products: EXPAREL, ZILRETTA, and iovera.
• The company is reliant on a limited number of wholesalers.
• The company is reliant on a limited number of manufacturing sites.
• The company is subject to risks related to cybersecurity.
• The company is subject to risks related to the outcome of ongoing litigation.

Future Outlook

The company expects that its cash and cash equivalents and available-for-sale investments on hand will be adequate to cover its short-term liquidity needs. The company also expects to continue to pursue the expanded use of EXPAREL, ZILRETTA and iovera in additional procedures; progress its earlier-stage product candidate pipeline; advance regulatory activities for EXPAREL, ZILRETTA, iovera, PCRX-201 and its other product candidates; invest in sales and marketing resources for EXPAREL, ZILRETTA and iovera; expand and enhance its manufacturing capacity for EXPAREL, ZILRETTA and iovera; invest in products, businesses and technologies; and support legal matters.

Management Comments

• The company is committed to vigorously defending its EXPAREL intellectual property.
• The company is investing in programs to drive awareness and education for its customers and enhance its marketing, market access and reimbursement teams.
• The company is focused on ensuring audiences are ready for the commencement of the NOPAIN Act.

Industry Context

The company operates in the non-opioid pain management and regenerative health solutions market, which is experiencing growth due to increasing awareness of the risks associated with opioid use. The company's products, EXPAREL, ZILRETTA, and iovera, are positioned to address the growing demand for non-opioid pain management options. The company is also advancing the development of PCRX-201, a novel gene therapy for osteoarthritis, which could provide a new treatment option for a large patient population.

Comparison to Industry Standards

• Pacira's revenue growth of 3% in Q3 2024 is modest compared to some high-growth biotech companies, but is in line with established pharmaceutical companies.
• The goodwill impairment charge of $163.2 million is a significant event and is not typical for established companies, indicating a potential overvaluation of assets or a significant change in market conditions.
• The company's focus on non-opioid pain management aligns with current industry trends and regulatory initiatives, such as the NOPAIN Act.
• The company's investment in a gene therapy product candidate, PCRX-201, is consistent with the industry's move towards innovative therapies for chronic conditions.
• The company's debt levels, including convertible senior notes and term loans, are typical for companies in the biotech sector, which often rely on debt financing for growth and acquisitions.
• The company's legal challenges, including patent litigation, are common in the pharmaceutical industry, where intellectual property protection is critical.

Management Changes

Legal Proceedings

• The company is involved in ongoing patent infringement lawsuits against eVenus Pharmaceutical Laboratories, Inc. and its parent company.
• The company is involved in a lawsuit with Fortis Advisors LLC related to milestone payments under the MyoScience Merger Agreement.
• The company is involved in a lawsuit with the Research Development Foundation regarding royalty obligations.

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and goodwill impairment.
• Employees may be affected by the restructuring plan and potential changes in operations.
• Customers may benefit from the company's continued focus on non-opioid pain management solutions.
• Suppliers may be affected by changes in the company's manufacturing and supply chain operations.
• Creditors may be impacted by the company's debt levels and financial performance.

Next Steps

• The company will continue to pursue the expanded use of EXPAREL, ZILRETTA and iovera in additional procedures.
• The company will progress its earlier-stage product candidate pipeline.
• The company will advance regulatory activities for EXPAREL, ZILRETTA, iovera, PCRX-201 and its other product candidates.
• The company will invest in sales and marketing resources for EXPAREL, ZILRETTA and iovera.
• The company will expand and enhance its manufacturing capacity for EXPAREL, ZILRETTA and iovera.
• The company will invest in products, businesses and technologies.
• The company will support legal matters.

Key Dates

Keywords

EXPAREL, ZILRETTA, iovera, Goodwill Impairment, Patent Litigation, Non-Opioid Pain Management, Convertible Senior Notes, Share Repurchase, Medicare Reimbursement, NOPAIN Act